Simons Kurt
Pediatric Vision Laboratory, Krieger Children's Eye Center, Wilmer Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-9028, USA.
Surv Ophthalmol. 2005 Mar-Apr;50(2):123-66. doi: 10.1016/j.survophthal.2004.12.005.
Amblyopia has a 1.6-3.6% prevalence, higher in the medically underserved. It is more complex than simply visual acuity loss and the better eye has sub-clinical deficits. Functional limitations appear more extensive and loss of vision in the better eye of amblyopes more prevalent than previously thought. Amblyopia screening and treatment are efficacious, but cost-effectiveness concerns remain. Refractive correction alone may successfully treat anisometropic amblyopia and it, minimal occlusion, and/or catecholamine treatment can provide initial vision improvement that may improve compliance with subsequent long-duration treatment. Atropine penalization appears as effective as occlusion for moderate amblyopia, with limited-day penalization as effective as full-time. Cytidin-5'-diphosphocholine may hold promise as a medical treatment. Interpretation of much of the amblyopia literature is made difficult by: inaccurate visual acuity measurement at initial visit, lack of adequate refractive correction prior to and during treatment, and lack of long-term follow-up results. Successful treatment can be achieved in at most 63-83% of patients. Treatment outcome is a function of initial visual acuity and type of amblyopia, and a reciprocal product of treatment efficacy, duration, and compliance. Age at treatment onset is not predictive of outcome in many studies but detection under versus over 2-3 years of age may be. Multiple screenings prior to that age, and prompt treatment, reduce prevalence. Would a single early cycloplegic photoscreening be as, or more, successful at detection or prediction than the multiple screenings, and more cost-effective? Penalization and occlusion have minimal incidence of reverse amblyopia and/or side-effects, no significant influence on emmetropization, and no consistent effect on sign or size of post-treatment changes in strabismic deviation. There may be a physiologic basis for better age-indifferent outcome than tapped by current treatment methodologies. Infant refractive correction substantially reduces accommodative esotropia and amblyopia incidence without interference with emmetropization. Compensatory prism, alone or post-operatively, and/or minus lens treatment, and/or wide-field fusional amplitude training, may reduce risk of early onset esotropia. Multivariate screening using continuous-scale measurements may be more effective than traditional single-test dichotomous pass/fail measures. Pigmentation may be one parameter because Caucasians are at higher risk for esotropia than non-whites.
弱视的患病率为1.6%-3.6%,在医疗服务不足地区更高。它比单纯的视力丧失更为复杂,较好的眼睛存在亚临床缺陷。功能限制似乎更为广泛,弱视患者较好眼睛的视力丧失比以前认为的更为普遍。弱视筛查和治疗是有效的,但成本效益问题仍然存在。单纯屈光矫正可能成功治疗屈光参差性弱视,而最小化遮盖和/或儿茶酚胺治疗可提供初始视力改善,这可能提高对后续长期治疗的依从性。对于中度弱视,阿托品压抑疗法似乎与遮盖疗法一样有效,有限天数的压抑疗法与全天压抑疗法效果相同。胞苷-5'-二磷酸胆碱可能有望成为一种药物治疗方法。许多弱视文献的解读因以下因素而变得困难:初诊时视力测量不准确、治疗前及治疗期间屈光矫正不足以及缺乏长期随访结果。最多63%-83%的患者可实现成功治疗。治疗结果取决于初始视力和弱视类型,以及治疗效果、持续时间和依从性的相互乘积。在许多研究中,治疗开始时的年龄并不能预测结果,但2-3岁之前或之后被发现可能会有影响。在该年龄之前进行多次筛查并及时治疗可降低患病率。单次早期睫状肌麻痹验光筛查在检测或预测方面是否与多次筛查一样成功或更成功,且成本效益更高?压抑疗法和遮盖疗法导致反向弱视和/或副作用的发生率极低,对正视化无显著影响,对斜视偏差治疗后变化的体征或大小也无一致影响。可能存在一种生理基础,使得治疗结果比当前治疗方法更不受年龄影响。婴儿期屈光矫正可大幅降低调节性内斜视和弱视的发生率,而不会干扰正视化。单独或术后使用补偿棱镜,和/或负透镜治疗,和/或宽视野融合幅度训练,可能会降低早期内斜视的风险。使用连续量表测量的多变量筛查可能比传统的单测试二分法通过/失败测量更有效。色素沉着可能是一个参数,因为白种人患内斜视的风险高于非白种人。